{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:58:21Z","timestamp":1784926701860,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,17]]},"DOI":"10.7759\/cureus.52452","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T18:27:41Z","timestamp":1705516061000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effects of Benralizumab on Lung Volumes and Airway Resistance in Severe Eosinophilic Asthma: A Real-World Study"],"prefix":"10.7759","author":[{"given":"Ant\u00f3nio","family":"Madeira Gerardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"da Silva Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia","family":"Pardal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedi","family":"Liberato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda S","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Duarte-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung KF","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, et al.. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014, 43:343-73. 10.1183\/09031936.00202013","journal-title":"Eur Respir J"},{"key":"ref2","unstructured":"Global Surveillance, Prevention and Control of Chronic Respiratory Diseases. (2007). https.\/\/www.who.int\/publications\/i\/item\/global-surveillance-prevention-and-control-of-chronic-respiratory-diseases."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/2045-7022-2-15","article-title":"Prevalence of asthma in Portugal - the Portuguese National Asthma survey","volume":"2","author":"Sa-Sousa A","year":"2012","unstructured":"Sa-Sousa A, Morais-Almeida M, Azevedo LF, et al.. Prevalence of asthma in Portugal - the Portuguese National Asthma survey. Clin Transl Allergy. 2012, 2:15. 10.1186\/2045-7022-2-15","journal-title":"Clin Transl Allergy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich F","year":"2014","unstructured":"Schleich F, Brusselle G, Louis R, et al.. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014, 108:1723-32. 10.1016\/j.rmed.2014.10.007","journal-title":"Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000346","article-title":"Asthma guidelines: the global initiative for asthma in relation to national guidelines","volume":"17","author":"Becker AB","year":"2017","unstructured":"Becker AB, Abrams EM. Asthma guidelines: the global initiative for asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol. 2017, 17:99-103. 10.1097\/ACI.0000000000000346","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref6","unstructured":"2023 GINA Report, Global Strategy for Asthma Management and Prevention. (2023). Accessed. October 20, 2023: https:\/\/ginasthma.org\/2023-gina-main-report\/."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia C","year":"2022","unstructured":"Pelaia C, Heffler E, Crimi C, Maglio A, Vatrella A, Pelaia G, Canonica GW. Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets. Front Pharmacol. 2022, 13:851940. 10.3389\/fphar.2022.851940","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran TN","year":"2016","unstructured":"Tran TN, Zeiger RS, Peters SP, Colice G, Newbold P, Goldman M, Chipps BE. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016, 116:37-42. 10.1016\/j.anai.2015.10.027","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure A","year":"2016","unstructured":"Froidure A, Mouthuy J, Durham SR, Chanez P, Sibille Y, Pilette C. Asthma phenotypes and IgE responses. Eur Respir J. 2016, 47:304-19. 10.1183\/13993003.01824-2014","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114112","article-title":"The management of severe asthma in 2020","volume":"179","author":"C\u00f4t\u00e9 A","year":"2020","unstructured":"C\u00f4t\u00e9 A, Godbout K, Boulet LP. The management of severe asthma in 2020. Biochem Pharmacol. 2020, 179:114112. 10.1016\/j.bcp.2020.114112","journal-title":"Biochem Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S272681","article-title":"Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States","volume":"13","author":"Song HJ","year":"2020","unstructured":"Song HJ, Blake KV, Wilson DL, Winterstein AG, Park H. Medical costs and productivity loss due to mild, moderate, and severe asthma in the United States. J Asthma Allergy. 2020, 13:545-55. 10.2147\/JAA.S272681","journal-title":"J Asthma Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes PJ","year":"2013","unstructured":"Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013, 131:636-45. 10.1016\/j.jaci.2012.12.1564","journal-title":"J Allergy Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia C","year":"2020","unstructured":"Pelaia C, Busceti MT, Crimi C, et al.. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020, 129:110444. 10.1016\/j.biopha.2020.110444","journal-title":"Biomed Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105189","article-title":"Why do some asthma patients respond poorly to glucocorticoid therapy?","volume":"160","author":"Henderson I","year":"2020","unstructured":"Henderson I, Caiazzo E, McSharry C, Guzik TJ, Maffia P. Why do some asthma patients respond poorly to glucocorticoid therapy?. Pharmacol Res. 2020, 160:105189. 10.1016\/j.phrs.2020.105189","journal-title":"Pharmacol Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1705335","article-title":"Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways","volume":"58","author":"Cataldo D","year":"2021","unstructured":"Cataldo D, Louis R, Michils A, et al.. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021, 58:448-58. 10.1080\/02770903.2019.1705335","journal-title":"J Asthma"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1753440","article-title":"Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab","volume":"16","author":"Ridolo E","year":"2020","unstructured":"Ridolo E, Pucciarini F, Nizi MC, Makri E, Kihlgren P, Panella L, Incorvaia C. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother. 2020, 16:2349-56. 10.1080\/21645515.2020.1753440","journal-title":"Hum Vaccin Immunother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0144-2021","article-title":"A pragmatic guide to choosing biologic therapies in severe asthma","volume":"17","author":"Kavanagh JE","year":"2021","unstructured":"Kavanagh JE, Hearn AP, Jackson DJ. A pragmatic guide to choosing biologic therapies in severe asthma. Breathe (Sheff). 2021, 17:210144. 10.1183\/20734735.0144-2021","journal-title":"Breathe (Sheff)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi K","year":"2023","unstructured":"Oishi K, Hamada K, Murata Y, et al.. A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma. J Clin Med. 2023, 12:2900. 10.3390\/jcm12082900","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2020.1718495","article-title":"Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab","volume":"14","author":"Hillas G","year":"2020","unstructured":"Hillas G, Fouka E, Papaioannou AI. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020, 14:353-65. 10.1080\/17476348.2020.1718495","journal-title":"Expert Rev Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01134","article-title":"Biological therapies of severe asthma and their possible effects on airway remodeling","volume":"11","author":"Kardas G","year":"2020","unstructured":"Kardas G, Kuna P, Panek M. Biological therapies of severe asthma and their possible effects on airway remodeling. Front Immunol. 2020, 11:1134. 10.3389\/fimmu.2020.01134","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker ER","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, et al.. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016, 388:2115-27. 10.1016\/S0140-6736(16)31324-1","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald JM","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al.. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016, 388:2128-41. 10.1016\/S0140-6736(16)31322-8","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache I","year":"2020","unstructured":"Agache I, Beltran J, Akdis C, et al.. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020, 75:1023-42. 10.1111\/all.14221","journal-title":"Allergy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by Biologics targeting IL5\/Il5r: results from a multicenter real-life study","volume":"24","author":"Maglio A","year":"2023","unstructured":"Maglio A, Vitale C, Pelaia C, et al.. Severe asthma remissions induced by Biologics targeting IL5\/Il5r: results from a multicenter real-life study. Int J Mol Sci. 2023, 24:2455. 10.3390\/ijms24032455","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S240044","article-title":"Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: Phase IIIb randomized, controlled trial (Solana)","volume":"13","author":"Panettieri RA Jr","year":"2020","unstructured":"Panettieri RA Jr, Welte T, Shenoy KV, et al.. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: Phase IIIb randomized, controlled trial (Solana). J Asthma Allergy. 2020, 13:115-26. 10.2147\/JAA.S240044","journal-title":"J Asthma Allergy"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson GT","year":"2017","unstructured":"Ferguson GT, FitzGerald JM, Bleecker ER, et al.. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017, 5:568-76. 10.1016\/S2213-2600(17)30190-X","journal-title":"Lancet Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/216521-the-effects-of-benralizumab-on-lung-volumes-and-airway-resistance-in-severe-eosinophilic-asthma-a-real-world-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:18Z","timestamp":1707509538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/216521-the-effects-of-benralizumab-on-lung-volumes-and-airway-resistance-in-severe-eosinophilic-asthma-a-real-world-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.52452","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,17]]}}}